Immunome doses first patient in IM-3050 cancer therapy trial

Markets Investing.com By Investing.com 20 Jul 2026 11:37 1 min read

Immunome doses first patient in IM-3050 cancer therapy trial

Immunome doses first patient in IM-3050 cancer therapy trial

Immunome doses first patient in IM-3050 cancer therapy trial

Read the full story on Investing.com → Opens the original article on www.investing.com

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.